Cargando…

Recombinant expression of SARS-CoV-2 receptor binding domain (RBD) in Escherichia coli and its immunogenicity in mice

OBJECTIVE(S): The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), giving rise to the coronavirus disease 2019 (COVID-19), has become a danger to wellbeing worldwide. Thus, finding efficient and safe vaccines for COVID-19 is of great importance. As a basic step amid contamination, SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahbar, Zahra, Nazarian, Shahram, Dorostkar, Ruhollah, Sotoodehnejadnematalahi, Fattah, Amani, Jafar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526882/ https://www.ncbi.nlm.nih.gov/pubmed/36246069 http://dx.doi.org/10.22038/IJBMS.2022.65045.14333

Ejemplares similares

Antigenicity and immunogenicity of SARS-CoV-2 surface glycoprotein fragment in CHO cells
por: Karimi, Sahar, et al.
Publicado: (2023)

Immunogenicity of inactivated Escherichia coli O157:H7 with Stx2B microparticle in mice
por: Arshadi, Nasim, et al.
Publicado: (2022)

Immunogenicity of the nanovaccine containing intimin recombinant protein in the BALB/c mice
por: Hosseini, Zahra Sadat, et al.
Publicado: (2018)

Immunogenic evaluation of chimeric recombinant protein against ETEC, EHEC and Shigella
por: Khalouie, Farzane, et al.
Publicado: (2017)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

Immunogenic Potency of Formalin and Heat Inactivated E. coli O157:H7 in Mouse Model Administered by Different Routes
por: Arshadi, Nasim, et al.
Publicado: (2020)

Immunogenic Domains and Secondary Structure of Escherichia coli Recombinant Secreted Protein Escherichia coli-Secreted Protein B
por: Caetano, Bruna Alves, et al.
Publicado: (2017)

Preparation of chitosan nanoparticle containing recombinant StxB antigen of EHEC and evaluation its immunogenicity in BALB/c mice
por: Almasian, Pegah, et al.
Publicado: (2018)

Immunogenicity of enterotoxigenic Escherichia coli outer membrane vesicles encapsulated in chitosan nanoparticles
por: Noroozi, Nafiseh, et al.
Publicado: (2018)

Immunogenicity of a Fusion Protein Comprising Coli Surface Antigen 3 and Labile B Subunit of Enterotoxigenic Escherichia coli
por: Alerasol, Masoome, et al.
Publicado: (2014)

Immunogenicity of Cork and Loop Domains of Recombinant Baumannii acinetobactin Utilization Protein in Murine Model
por: Esmaeilkhani, Hamid, et al.
Publicado: (2019)

Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines
por: Scaria, Puthupparampil V., et al.
Publicado: (2022)

Detection of E. coli O157:H7 and Shigella dysenteriae toxins in clinical samples by PCR-ELISA
por: Amani, Jafar, et al.
Publicado: (2015)

Passive immunization by recombinant ferric enterobactin protein (FepA) from Escherichia coli O157
por: Larrie-Bagha, Seyed Mehdi, et al.
Publicado: (2013)

Evaluation of PLGA-Encapsulated Recombinant GroEL of S. typhi immune Responses Against Enterohaemorrhagic and Enteropathogenic Escherichia coli
por: Parvane, Milad, et al.
Publicado: (2022)

In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications
por: Amani, Jafar, et al.
Publicado: (2009)

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
por: Leal, Lorna, et al.
Publicado: (2023)

Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of Escherichia coli
por: Kim, Woo Sung, et al.
Publicado: (2022)

Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models
por: Nazarian, Shahram, et al.
Publicado: (2022)

Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBD(N318-V510)) Expressed in Escherichia coli
por: Márquez-Ipiña, Alan Roberto, et al.
Publicado: (2021)

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast
por: Nagar, Gaurav, et al.
Publicado: (2023)

In vitro immunogenic profile of recombinant SARS-CoV2 S1-RBD peptide in murine macrophage and microglial cells
por: Chaves, Adriano José Maia, et al.
Publicado: (2023)

An LTB-entrapped protein in PLGA nanoparticles preserves against enterotoxin of enterotoxigenic Escherichia coli
por: Kordbacheh, Emad, et al.
Publicado: (2018)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

Author Correction: Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Protective Immunity Against Enterotoxigenic Escherichia coli by Oral Vaccination of Engineered Lactococcus lactis
por: Ahmadi Rouzbahani, Homa, et al.
Publicado: (2021)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

Utilization of Recombinant Baculovirus Expression System to Produce the RBD Domain of SARS-CoV-2 Spike Protein
por: Fan, Youpeng, et al.
Publicado: (2022)

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice
por: Govea-Alonso, Dania O., et al.
Publicado: (2022)

Escherichia coli lipoprotein binds human plasminogen via an intramolecular domain
por: Gonzalez, Tammy, et al.
Publicado: (2015)

Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle
por: Kerner, Katharina, et al.
Publicado: (2015)

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
por: Bajoria, Sakshi, et al.
Publicado: (2022)

Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2022)

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells
por: Gerez, Guillaume, et al.
Publicado: (2022)

Immunogenicity of the Multi-Epitopic Recombinant Glycoproteins of Newcastle Disease Virus: Implications for the Serodiagnosis Applications
por: Motamedi, Mohammad Javad, et al.
Publicado: (2018)

Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
por: Mehalko, Jennifer, et al.
Publicado: (2020)

Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
por: Mehalko, Jennifer, et al.
Publicado: (2021)

SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study)
por: Hajizadeh, Faezeh, et al.
Publicado: (2022)

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
por: Kaewchim, Kanasap, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4k4bup4jtadjkvbr8episjlnra